The Food and Drug Administration is investigating whether Fresenius Medical Care, the nation's largest operator of dialysis centers, violated federal regulations by failing to inform customers of a potentially lethal risk connected to one of its products, an FDA official said.
Fresenius' failure to warn of risk draws inquiry
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.